PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of PI3K inhibitor BKM120 when given
together with carboplatin and pemetrexed disodium in treating patients with stage IV
non-small cell lung cancer. PI3K inhibitor BKM120 and pemetrexed disodium may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving PI3K inhibitor BKM120,
carboplatin, and pemetrexed disodium together may kill more tumor cells